{"count": 159, "results": [{"_id": "37026076", "pmid": 37026076, "pmcid": "PMC10072834", "title": "Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors", "journal": "Open Vet J", "authors": ["Kellon EM", "Gustafson KM"], "date": "2023-03-01T00:00:00Z", "doi": "10.5455/OVJ.2023.v13.i3.14", "meta_date_publication": "2023 Mar", "meta_volume": "13", "meta_issue": "3", "meta_pages": "365-375", "score": 50261.92, "text_hl": "This was a 23-year-old Arabian gelding with a history of laminitis for 2 years. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ therapy was trialed but while initially helpful, over time it was less effective and could no longer control @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@. ", "citations": {"NLM": "Kellon EM, Gustafson KM. Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors Open Vet J. 2023 Mar;13(3):365-375. PMID: 37026076", "BibTeX": "@article{37026076, title={Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors}, author={Kellon EM and Gustafson KM}, journal={Open Vet J}, volume={13}, number={3}, pages={365-375}}"}}, {"_id": "38001929", "pmid": 38001929, "pmcid": "PMC10669553", "title": "The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment", "journal": "Biomedicines", "authors": ["Fazio S", "Mercurio V", "Affuso F", "Bellavite P"], "date": "2023-10-30T00:00:00Z", "doi": "10.3390/biomedicines11112928", "meta_date_publication": "2023 Oct 30", "meta_volume": "11", "meta_issue": "11", "meta_pages": "", "score": 50257.03, "text_hl": "To date, several substances have been shown to reduce @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@IR@@@/@<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@ and have beneficial clinical effects in @SPECIES_9606 @@@patients@@@ with @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@HF@@@, including @GENE_SLC5A2 @GENE_6524 @@@SGLT2@@@ inhibitors, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and @CHEMICAL_Berberine @CHEMICAL_MESH:D001599 @@@berberine@@@. ", "citations": {"NLM": "Fazio S, Mercurio V, Affuso F, Bellavite P. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment Biomedicines. 2023 Oct 30;11(11):. PMID: 38001929", "BibTeX": "@article{38001929, title={The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment}, author={Fazio S and Mercurio V and Affuso F and Bellavite P}, journal={Biomedicines}, volume={11}, number={11}}"}}, {"_id": "36118716", "pmid": 36118716, "pmcid": "PMC9473365", "title": "Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis", "journal": "Open Vet J", "authors": ["Kellon EM", "Gustafson KM"], "date": "2022-07-01T00:00:00Z", "doi": "10.5455/OVJ.2022.v12.i4.14", "meta_date_publication": "2022 Jul-Aug", "meta_volume": "12", "meta_issue": "4", "meta_pages": "511-518", "score": 50255.508, "text_hl": "Except for one mention of @CHEMICAL_Glyburide @CHEMICAL_MESH:D005905 @@@glyburide@@@, the only published commercially available pharmacological option for @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@ in @SPECIES_9796 @@@horses@@@ is @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Kellon EM, Gustafson KM. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis Open Vet J. 2022 Jul-Aug;12(4):511-518. PMID: 36118716", "BibTeX": "@article{36118716, title={Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis}, author={Kellon EM and Gustafson KM}, journal={Open Vet J}, volume={12}, number={4}, pages={511-518}}"}}, {"_id": "34787028", "pmid": 34787028, "title": "Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.", "journal": "Gynecol Endocrinol", "authors": ["Hernández-Jiménez JL", "Barrera D", "Espinoza-Simón E", "González J", "Ortíz-Hernández R", "Escobar L", "Echeverría O", "Torres-Ramírez N"], "date": "2022-01-01T00:00:00Z", "doi": "10.1080/09513590.2021.2003326", "meta_date_publication": "2022 Jan", "meta_volume": "38", "meta_issue": "1", "meta_pages": "2-9", "score": 50250.254, "text_hl": "Therefore, we propose that treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could decrease @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@HI@@@ and consequently @DISEASE_Hyperandrogenism @DISEASE_MESH:D017588 @@@HA@@@, restoring, at least in part, the @DISEASE_Thyroid_Hormone_Metabolism_Abnormal @DISEASE_MESH:C566454 @@@metabolic and hormonal disorders@@@ of @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@.", "citations": {"NLM": "Hernández-Jiménez JL, Barrera D, Espinoza-Simón E, González J, Ortíz-Hernández R, Escobar L, Echeverría O, Torres-Ramírez N. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. Gynecol Endocrinol. 2022 Jan;38(1):2-9. PMID: 34787028", "BibTeX": "@article{34787028, title={Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.}, author={Hernández-Jiménez JL and Barrera D and Espinoza-Simón E and González J and Ortíz-Hernández R and Escobar L and Echeverría O and Torres-Ramírez N}, journal={Gynecol Endocrinol}, volume={38}, number={1}, pages={2-9}}"}}, {"_id": "36143915", "pmid": 36143915, "pmcid": "PMC9503803", "title": "Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy", "journal": "Medicina (Kaunas)", "authors": ["Gales L", "Forsea L", "Mitrea D", "Stefanica I", "Stanculescu I", "Mitrica R", "Georgescu M", "Trifanescu O", "Anghel R", "Serbanescu L"], "date": "2022-09-07T00:00:00Z", "doi": "10.3390/medicina58091239", "meta_date_publication": "2022 Sep 7", "meta_volume": "58", "meta_issue": "9", "meta_pages": "", "score": 50250.03, "text_hl": "Another possible research direction for @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ comes from adverse reactions to androgen-deprivation therapy, which is frequently employed in @DISEASE_Prostatic_Neoplasms @DISEASE_MESH:D011471 @@@prostate cancer@@@ management, such as @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obesity@@@, @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@, @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, and @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@. ", "citations": {"NLM": "Gales L, Forsea L, Mitrea D, Stefanica I, Stanculescu I, Mitrica R, Georgescu M, Trifanescu O, Anghel R, Serbanescu L. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy Medicina (Kaunas). 2022 Sep 7;58(9):. PMID: 36143915", "BibTeX": "@article{36143915, title={Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy}, author={Gales L and Forsea L and Mitrea D and Stefanica I and Stanculescu I and Mitrica R and Georgescu M and Trifanescu O and Anghel R and Serbanescu L}, journal={Medicina (Kaunas)}, volume={58}, number={9}}"}}, {"_id": "35986566", "pmid": 35986566, "pmcid": "PMC9470898", "title": "Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice", "journal": "Aging Cell", "authors": ["Reifsnyder PC", "Flurkey K", "Doty R", "Calcutt NA", "Koza RA", "Harrison DE"], "date": "2022-09-01T00:00:00Z", "doi": "10.1111/acel.13666", "meta_date_publication": "2022 Sep", "meta_volume": "21", "meta_issue": "9", "meta_pages": "e13666", "score": 50249.477, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ alone reduced @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@ and circulating @GENE_CRP @GENE_12944 @@@c-reactive protein@@@, but exacerbated @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@nephropathy@@@. ", "citations": {"NLM": "Reifsnyder PC, Flurkey K, Doty R, Calcutt NA, Koza RA, Harrison DE. Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice Aging Cell. 2022 Sep;21(9):e13666. PMID: 35986566", "BibTeX": "@article{35986566, title={Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice}, author={Reifsnyder PC and Flurkey K and Doty R and Calcutt NA and Koza RA and Harrison DE}, journal={Aging Cell}, volume={21}, number={9}, pages={e13666}}"}}, {"_id": "34484117", "pmid": 34484117, "pmcid": "PMC8414830", "title": "Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance", "journal": "Front Endocrinol (Lausanne)", "authors": ["Xie Y", "Xiao L", "Li S"], "date": "2021-08-13T00:00:00Z", "doi": "10.3389/fendo.2021.701590", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "701590", "score": 50249.332, "text_hl": "As @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@IR@@@ and the resulting @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@ are key metabolic features in @SPECIES_9606 @@@women@@@ with @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@, their amelioration through @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could improve @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@-associated symptoms and conception rates. ", "citations": {"NLM": "Xie Y, Xiao L, Li S. Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance Front Endocrinol (Lausanne). 2021;12():701590. PMID: 34484117", "BibTeX": "@article{34484117, title={Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance}, author={Xie Y and Xiao L and Li S}, journal={Front Endocrinol (Lausanne)}, volume={12}, pages={701590}}"}}, {"_id": "33742773", "pmid": 33742773, "pmcid": "PMC8504897", "title": "Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up", "journal": "J Diabetes Investig", "authors": ["Yin X", "Liu J", "Feng R", "Xu M", "Liu J"], "date": "2021-10-01T00:00:00Z", "doi": "10.1111/jdi.13549", "meta_date_publication": "2021 Oct", "meta_volume": "12", "meta_issue": "10", "meta_pages": "1919-1922", "score": 50247.06, "text_hl": "OGTT was carried out again, and showed a significant decrease of @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@ (Figure 1).", "citations": {"NLM": "Yin X, Liu J, Feng R, Xu M, Liu J. Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up J Diabetes Investig. 2021 Oct;12(10):1919-1922. PMID: 33742773", "BibTeX": "@article{33742773, title={Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up}, author={Yin X and Liu J and Feng R and Xu M and Liu J}, journal={J Diabetes Investig}, volume={12}, number={10}, pages={1919-1922}}"}}, {"_id": "32269725", "pmid": 32269725, "title": "Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.", "journal": "Am J Transl Res", "authors": ["Xiao H", "Huang X", "Wang S", "Liu Z", "Dong R", "Song D", "Dai H"], "date": "2020-03-15T00:00:00Z", "meta_date_publication": "2020", "meta_volume": "12", "meta_issue": "3", "meta_pages": "940-949", "score": 50246.875, "text_hl": "In the pathogenesis of @DISEASE_Idiopathic_Pulmonary_Fibrosis @DISEASE_MESH:D054990 @@@IPF@@@, @GENE_IGF1 @GENE_16000 @@@insulin-like growth factor-1@@@ (@GENE_IGF1 @GENE_16000 @@@IGF-1@@@) has been found to be heavily involved. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@, a commonly used oral antidiabetic agent, is known to inhibit @GENE_IGF1 @GENE_16000 @@@IGF-1@@@ by the reversal of @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@. ", "citations": {"NLM": "Xiao H, Huang X, Wang S, Liu Z, Dong R, Song D, Dai H. Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1. Am J Transl Res. 2020;12(3):940-949. PMID: 32269725", "BibTeX": "@article{32269725, title={Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.}, author={Xiao H and Huang X and Wang S and Liu Z and Dong R and Song D and Dai H}, journal={Am J Transl Res}, volume={12}, number={3}, pages={940-949}}"}}, {"_id": "36058289", "pmid": 36058289, "title": "Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle.", "journal": "Eur J Pharmacol", "authors": ["Cheng J", "Xu L", "Yu Q", "Lin G", "Ma X", "Li M", "Guan F", "Liu Y", "Huang X", "Xie J", "Chen J", "Su Z", "Li Y"], "date": "2022-10-15T00:00:00Z", "doi": "10.1016/j.ejphar.2022.175234", "meta_date_publication": "2022 Oct 15", "meta_volume": "933", "meta_issue": "", "meta_pages": "175234", "score": 50245.168, "text_hl": "Results indicated that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ significantly ameliorated features of @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, including body weight, Lee's index, @<m>DISEASE_Hyperinsulinism</m> @DISEASE_MESH:D006946 @@@hyperinsulinemia@@@, @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@dyslipidemia@@@, @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin intolerance@@@ and @DISEASE_Pancreatic_Diseases @DISEASE_MESH:D010182 @@@pancreatic damage@@@. ", "citations": {"NLM": "Cheng J, Xu L, Yu Q, Lin G, Ma X, Li M, Guan F, Liu Y, Huang X, Xie J, Chen J, Su Z, Li Y. Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle. Eur J Pharmacol. 2022 Oct 15;933():175234. PMID: 36058289", "BibTeX": "@article{36058289, title={Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle.}, author={Cheng J and Xu L and Yu Q and Lin G and Ma X and Li M and Guan F and Liu Y and Huang X and Xie J and Chen J and Su Z and Li Y}, journal={Eur J Pharmacol}, volume={933}, pages={175234}}"}}]}